Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Resmed Inc (RMD)

Resmed Inc (RMD)
185.31 x 1 225.19 x 1
Post-market by (Cboe BZX)
212.91 +1.42 (+0.67%) 04/17/25 [NYSE]
185.31 x 1 225.19 x 1
Post-market 212.91 unch (unch) 16:10 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
202.00
Day High
214.32
Open 209.00
Previous Close 211.49 211.49
Volume 1,109,500 1,109,500
Avg Vol 1,248,885 1,248,885
Stochastic %K 50.81% 50.81%
Weighted Alpha +6.68 +6.68
5-Day Change +2.36 (+1.12%) +2.36 (+1.12%)
52-Week Range 176.33 - 263.05 176.33 - 263.05
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,269,456
  • Shares Outstanding, K 146,867
  • Annual Sales, $ 4,685 M
  • Annual Income, $ 1,021 M
  • EBIT $ 1,605 M
  • EBITDA $ 1,821 M
  • 60-Month Beta 0.75
  • Price/Sales 6.63
  • Price/Cash Flow 22.92
  • Price/Book 5.91

Options Overview Details

View History
  • Implied Volatility 46.29% ( -3.01%)
  • Historical Volatility 37.53%
  • IV Percentile 89%
  • IV Rank 58.95%
  • IV High 63.20% on 08/01/24
  • IV Low 22.00% on 05/09/24
  • Put/Call Vol Ratio 0.64
  • Today's Volume 1,243
  • Volume Avg (30-Day) 601
  • Put/Call OI Ratio 2.41
  • Today's Open Interest 24,317
  • Open Int (30-Day) 22,381

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.36
  • Number of Estimates 7
  • High Estimate 2.41
  • Low Estimate 2.32
  • Prior Year 2.13
  • Growth Rate Est. (year over year) +10.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
199.92 +6.50%
on 04/07/25
Period Open: 224.74
227.00 -6.21%
on 03/25/25
-11.83 (-5.26%)
since 03/17/25
3-Month
199.92 +6.50%
on 04/07/25
Period Open: 239.78
263.05 -19.06%
on 01/30/25
-26.87 (-11.21%)
since 01/17/25
52-Week
176.33 +20.75%
on 04/18/24
Period Open: 173.83
263.05 -19.06%
on 01/30/25
+39.08 (+22.48%)
since 04/17/24

Most Recent Stories

More News
Earnings Preview: What to Expect From ResMed’s Report

ResMed is set to release its fiscal third-quarter earnings this month, with analysts forecasting a lower-double-digit growth in profits.

XLV : 135.49 (-0.59%)
$SPX : 5,282.70 (unch)
RMD : 212.91 (+0.67%)
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)

Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)

RMD : 212.91 (+0.67%)
MASI : 152.15 (+0.31%)
PODD : 246.80 (-1.57%)
IRTC : 100.96 (+1.01%)
DXCM : 68.57 (-0.23%)
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

RMD.AX : 33.610 (+1.73%)
RMD : 212.91 (+0.67%)
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks

Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks

RMD : 212.91 (+0.67%)
MASI : 152.15 (+0.31%)
IRTC : 100.96 (+1.01%)
PODD : 246.80 (-1.57%)
DXCM : 68.57 (-0.23%)
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

RMD.AX : 33.610 (+1.73%)
RMD : 212.91 (+0.67%)
Is West Pharmaceutical Services Stock Underperforming the S&P 500?

West Pharmaceutical Services has lagged behind the broader S&P 500 Index over the past year, but analysts remain highly optimistic about its future growth potential.

$SPX : 5,282.70 (unch)
RMD : 212.91 (+0.67%)
WST : 201.90 (-3.46%)
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

RMD : 212.91 (+0.67%)
MASI : 152.15 (+0.31%)
PODD : 246.80 (-1.57%)
IRTC : 100.96 (+1.01%)
DXCM : 68.57 (-0.23%)
Is ResMed Stock Outperforming the Dow?

Despite ResMed’s outperformance relative to the Dow Jones over the past year, analysts are cautiously optimistic about the stock’s prospects.

RMD : 212.91 (+0.67%)
$DOWI : 39,142.23 (-1.33%)
ISRG : 482.74 (+0.29%)
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

RMD.AX : 33.610 (+1.73%)
RMD : 212.91 (+0.67%)
2 Large-Cap Stocks with Exciting Potential and 1 to Avoid

2 Large-Cap Stocks with Exciting Potential and 1 to Avoid

NOC : 540.39 (+0.54%)
RMD : 212.91 (+0.67%)
PWR : 267.22 (-0.83%)
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic

For Immediate ReleaseChicago, IL – March 13, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVDA : 101.49 (-2.87%)
RMD : 212.91 (+0.67%)
GEHC : 62.37 (+1.45%)
MDT : 82.60 (-0.12%)
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus

The medical device industry is undergoing a profound change in 2025, driven by advancements in generative AI and agentic AI. At the forefront of this revolution are players like NVIDIA NVDA, whose AI computing...

NVDA : 101.49 (-2.87%)
RMD : 212.91 (+0.67%)
GEHC : 62.37 (+1.45%)
MDT : 82.60 (-0.12%)
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

RMD.AX : 33.610 (+1.73%)
RMD : 212.91 (+0.67%)
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)

Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)

RMD : 212.91 (+0.67%)
MASI : 152.15 (+0.31%)
IRTC : 100.96 (+1.01%)
PODD : 246.80 (-1.57%)
DXCM : 68.57 (-0.23%)
VEEV Stock Gains Following Latest Availability of HCP Access Data

Veeva Systems Inc. VEEV, on Tuesday, announced Veeva CRM Pulse. It is a data subscription that provides quarterly healthcare professional (HCP) access and multichannel engagement metrics for the life sciences...

BSX : 95.12 (-0.14%)
RMD : 212.91 (+0.67%)
VEEV : 215.95 (-2.13%)
CAH : 134.71 (+0.26%)
VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation

Veeva Systems Inc. VEEV, on Thursday, announced that Direct Data API is now included for no additional license fee as part of Veeva Vault Platform. This is expected to enable AI innovation in the life...

BSX : 95.12 (-0.14%)
RMD : 212.91 (+0.67%)
VEEV : 215.95 (-2.13%)
CAH : 134.71 (+0.26%)
2 Reasons to Like RMD and 1 to Stay Skeptical

2 Reasons to Like RMD and 1 to Stay Skeptical

RMD : 212.91 (+0.67%)
SOLV Stock Down Despite Q4 Earnings & Revenues Beat Estimates

Solventum SOLV reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.41, which beat the Zacks Consensus Estimate of $1.31 by 7.6%. The bottom line declined 35% year over year.GAAP EPS...

SOLV : 66.26 (+0.90%)
BSX : 95.12 (-0.14%)
RMD : 212.91 (+0.67%)
CAH : 134.71 (+0.26%)
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)

Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)

RMD : 212.91 (+0.67%)
MASI : 152.15 (+0.31%)
PODD : 246.80 (-1.57%)
IRTC : 100.96 (+1.01%)
DXCM : 68.57 (-0.23%)
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours

Alcon, Inc. ALC delivered fourth-quarter 2024 core earnings per share (EPS) of 72 cents, up 2.9% from the year-ago quarter’s figure (up 3% at constant exchange rate or CER). The figure topped the Zacks...

RMD : 212.91 (+0.67%)
ALC : 92.54 (+0.53%)
PODD : 246.80 (-1.57%)
CAH : 134.71 (+0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory...

See More

Key Turning Points

3rd Resistance Point 229.81
2nd Resistance Point 222.06
1st Resistance Point 217.49
Last Price 212.91
1st Support Level 205.17
2nd Support Level 197.42
3rd Support Level 192.85

See More

52-Week High 263.05
Fibonacci 61.8% 229.92
Fibonacci 50% 219.69
Last Price 212.91
Fibonacci 38.2% 209.46
52-Week Low 176.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro